Evolving approaches of hematopoietic stem cell-based therapies to induce tolerance to organ transplants: The long road to tolerance

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 1, 2013, Pages 36-45

  Leventhal, J ^a   Miller, J ^a   Abecassis, M ^a   Tollerud, D J ^b,c   Ildstad, S T ^b,c  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b Regenerex LLC   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ALEMTUZUMAB; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ARTICLE; B LYMPHOCYTE; BIOENGINEERING; BONE MARROW BIOPSY; BONE MARROW CELL; CATTLE; CD4+ CD25+ T LYMPHOCYTE; CELL TYPE; CHIMERA; CLINICAL TRIAL (TOPIC); DONOR; DRUG DOSE TITRATION; ENGRAFTMENT SYNDROME; ERYTHROCYTE; FACILITATING CELL; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HLA MATCHING; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MIXED LYMPHOCYTE REACTION; NONHUMAN; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; PHYSICAL TOLERANCE; PLACENTA; PRIORITY JOURNAL; RADIATION DOSE; REGULATORY T LYMPHOCYTE; SAFETY; SEPSIS; SKIN ALLOGRAFT; WHOLE BODY RADIATION;

ANIMALS; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTS;

EID: 84871294408     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.201     Document Type: Article

References (75)

1. Burroughs, L.M. et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol. Blood Marrow Transplant. 14, 1279-1287 (2008).
2. Dausset, J., Colombani, J., Legrand, L., Feingold, N. & Rapaport, F.T. Genetic and biological aspects of the HL-A system of human histocompatibility. Blood 35, 591-612 (1970).
3. Billingham, R.E., Brent, L. & Medawar, P.B. Actively acquired tolerance of foreign cells. Nature 172, 603-606 (1953).
4. Owen, R.D. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 102, 400-401 (1945).
5. Ravindra, K.V., Wu, S., McKinney, M., Xu, H. & Ildstad, S.T. Composite tissue allotransplantation: Current challenges. Transplant. Proc. 41, 3519-3528 (2009).
6. Meier-Kriesche, H.U., Schold, J.D. & Kaplan, B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am. J. Transplant. 4, 1289-1295 (2004).
7. Feng, S. et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 307, 283-293 (2012).
8. Levitsky, J. Operational tolerance: Past lessons and future prospects. Liver Transpl. 17, 222-232 (2011).
9. Newell, K.A. et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Invest. 120, 1836-1847 (2010).
10. Orlando, G. et al. Clinical operational tolerance after renal transplantation: Current status and future challenges. Ann. Surg. 252, 915-928 (2010).
11. Pelletier, R.P. et al. Acute rejection following renal transplantation. Evidence that severity is the best predictor of subsequent graft survival time. Clin. Transplant. 12, 543-552 (1998).
12. Mao, Q. et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am. J. Transplant. 7, 864-871 (2007).
13. Markmann, J.F. & Kawai, T. The quest for transplantation tolerance: Have we finally sipped from the cup? Sci. Transl. Med. 4, 124fs5 (2012).
14. Main, J.M. & Prehn, R.T. Fate of skin homografts in x-irradiated mice treated with homologous marrow. J. Natl. Cancer Inst. 19, 1053-1064 (1957).
15. Weiden, P.L., Storb, R., Tsoi, M.S., Graham, T.C., Lerner, K.G. & Thomas, E.D. Infusion of donor lymphocytes into stable canine radiation chimeras: Implications for mechanism of transplantation tolerance. J. Immunol. 116, 1212-1219 (1976).
16. Lorenz, E., Uphoff, D., Reid, T.R. & Shelton, E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J. Natl. Cancer Inst. 12, 197-201 (1951).
17. Main, J.M. & Prehn, R.T. Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. J. Natl. Cancer Inst. 15, 1023-1029 (1955).
18. Rapaport, F.T., Cannon, F.D., Blumenstock, D.A., Watanabe, K. & Ferrebee, J.W. Induction of unresponsiveness to canine renal allografts by total body irradiation and bone marrow transplantation. Nature New Biol. 235, 191-192 (1972).
19. Thomas, E.D. A history of haemopoietic cell transplantation. Br. J. Haematol. 105, 330-339 (1999).
20. Gozzo, J.J., Wood, M.L. & Monaco, A.P. Use of allogenic, homozygous bone marrow cells for the induction of specific immunologic tolerance in mice treated with antilymphocyte serum. Surg. Forum 21, 281-284 (1970).
21. Monaco, A.P., Clark, A.W., Wood, M.L., Sahyoun, A.I., Codish, S.D. & Brown, R.W. Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: Case report of an initial attempt. Surgery 79, 384-392 (1976).
22. Barber, W.H. et al. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 51, 70-75 (1991).
23. Gammie, J.S. & Pham, S.M. Simultaneous donor bone marrow and cardiac transplantation: Can tolerance be induced with the development of chimerism? Curr. Opin. Cardiol. 14, 126-132 (1999).
24. Starzl, T.E. & Zinkernagel, R.M. Antigen localization and migration in immunity and tolerance. N. Engl. J. Med. 339, 1905-1913 (1998).
25. van Twuyver, E. et al. Pretransplantation blood transfusion revisited. N. Engl. J. Med. 325, 1210-1213 (1991).
26. van der Mast, B.J. et al. Modulation of the T cell compartment by blood transfusion. Effect on cytotoxic and helper T lymphocyte precursor frequencies and T cell receptor Vbeta usage. Transplantation 63, 1145-1154 (1997).
27. Ildstad, S.T. & Sachs, D.H. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 307, 168-170 (1984).
28. Sharabi, Y. & Sachs, D.H. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J. Exp. Med. 169, 493-502 (1989).
29. Colson, Y.L. et al. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J. Immunol. 155, 4179-4188 (1995).
30. Colson, Y.L., Li, H., Boggs, S.S., Patrene, K.D., Johnson, P.C. & Ildstad, S.T. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J. Immunol. 157, 2820-2829 (1996).
31. Slavin, S., Strober, S., Fukes, Z. & Kaplan, H.S. Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice. Long-term survival of allogeneic bone marrow and skin grafts. J. Exp. Med. 146, 34-48 (1977).
32. Millan, M.T. et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 73, 1386-1391 (2002).
33. Scandling, J.D. et al. Tolerance and chimerism after renal and hematopoieticcell transplantation. N. Engl. J. Med. 358, 362-368 (2008).
34. Scandling, J.D., Busque, S., Shizuru, J.A., Engleman, E.G. & Strober, S. Induced immune tolerance for kidney transplantation. N. Engl. J. Med. 365, 1359-1360 (2011).
35. Scandling, J.D. et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am. J. Transplant. 12, 1133-1145 (2012).
36. Luznik, L., Engstrom, L.W., Iannone, R. & Fuchs, E.J. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol. Blood Marrow Transplant. 8, 131-138 (2002).
37. Luznik, L., Jalla, S., Engstrom, L.W., Iannone, R. & Fuchs, E.J. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 98, 3456-3464 (2001).
38. Pham, S.M. et al. A clinical trial combining donor bone marrow infusion and heart transplantation: Intermediate-term results. J. Thorac. Cardiovasc. Surg. 119, 673-681 (2000).
39. Cirocco, R.E. et al. FoxP3 mRNA transcripts and regulatory cells in renal transplant recipients 10 years after donor marrow infusion. Transplantation 83, 1611-1619 (2007).
40. Hu, S.K., Eardley, D.D., Cantor, H. & Gershon, R.K. Definition of two pathways for generation of suppressor T-cell activity. Proc. Natl. Acad. Sci. U.S.A. 80, 3779-3781 (1983).
41. Kilshaw, P.J., Brent, L. & Pinto, M. Suppressor T cells in mice made unresponsive to skin allografts. Nature 255, 489-491 (1975).
42. Seigler, H.F., Ward, F.E., McCoy, R.E., Weinerth, J.L., Gunnells, J.C. & Stickel, D.L. Long-term results with forty-five living related renal allograft recipients genotypically identical for HLA. Surgery 81, 274-283 (1977).
43. van de Wetering, J., Gerrits, J.H., van Besouw, N.M., IJzermans, J.N. & Weimar, W. Successful tapering of immunosuppression to low-dose monotherapy steroids after living-related human leukocyte antigen-identical renal transplantation. Transplantation 87, 740-744 (2009).
44. Medawar, P.B. The use of antigenic tissue extracts to weaken the immunological reaction against skin homografts in mice. Transplantation 1, 21-38 (1963).
45. Martinez, C., Shapiro, F. & Good, R.A. Effect of the amount of tissue grafted upon survival of skin homografts. Proc. Soc. Exp. Biol. Med. 106, 476-480 (1961).
46. Heidt, S., Hester, J., Shankar, S., Friend, P.J. & Wood, K.J. B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells. Am. J. Transplant. 12, 1784-1792 (2012).
47. Levitsky, J. et al. The human "Treg MLR": Immune monitoring for FOXP3+ T regulatory cell generation. Transplantation 88, 1303-1311 (2009).
48. Kaplan, H.S. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology 78, 553-561 (1962).
49. Howard, R.J. et al. Kidney allograft survival in dogs treated with total lymphoid irradiation. Ann. Surg. 193, 196-200 (1981).
50. Najarian, J.S. et al. Fractionated total lymphoid irradiation as preparative immunosuppression in high risk renal transplantation: Clinical and immunological studies. Ann. Surg. 196, 442-452 (1982).
51. Sachs, D.H., Sykes, M., Kawai, T. & Cosimi, A.B. Immuno-intervention for the induction of transplantation tolerance through mixed chimerism. Semin. Immunol. 23, 165-173 (2011).
52. Kawai, T. et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 358, 353-361 (2008).
53. Farris, A.B. et al. Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts. Am. J. Transplant. 11, 1464-1477 (2011).
54. Kawai, T., Cosimi, A.B. & Sachs, D.H. Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism. Curr. Opin. Organ Transplant. 16, 366-371 (2011).
55. LoCascio, S.A. et al. Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance. Transplantation 90, 1607-1615 (2010).
56. Storb, R. et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89, 3048-3054 (1997).
57. Fuchs, E.J., Huang, X.J. & Miller, J.S. HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol. Blood Marrow Transplant. 16, S57-S63 (2010).
58. Luznik, L. et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 115, 3224-3230 (2010).
59. Luznik, L. et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and highdose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 14, 641-650 (2008).
60. Kaufman, C.L., Colson, Y.L., Wren, S.M., Watkins, S., Simmons, R.L. & Ildstad, S.T. Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 84, 2436-2446 (1994).
61. Gandy, K.L., Domen, J., Aguila, H. & Weissman, I.L. CD8+TCR+ and CD8+TCRcells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. Immunity 11, 579-590 (1999).
62. Fugier-Vivier, I.J. et al. Plasmacytoid precursor dendritic cells facilitate allogeneic hematopoietic stem cell engraftment. J. Exp. Med. 201, 373-383 (2005).
63. Rezzoug, F. et al. TNF-alpha is critical to facilitate hemopoietic stem cell engraftment and function. J. Immunol. 180, 49-57 (2008).
64. Huang, Y., Bozulic, L.D., Miller, T., Xu, H., Hussain, L.R. & Ildstad, S.T. CD8α+plasmacytoid precursor DCs induce antigen-specific regulatory T cels that enhance HSC engraftment in vivo. Blood 117, 2494-2505 (2011).
65. Colson, Y.L., Christopher, K., Glickman, J., Taylor, K.N., Wright, R. & Perkins, D.L. Absence of clinical GVHD and the in vivo induction of regulatory T cells after transplantation of facilitating cells. Blood 104, 3829-3835 (2004).
66. Schuchert, M.J., Wright, R.D. & Colson, Y.L. Characterization of a newly discovered T-cell receptor beta-chain heterodimer expressed on a CD8+ bone marrow subpopulation that promotes allogeneic stem cell engraftment. Nat. Med. 6, 904-909 (2000).
67. Leventhal, J. et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci. Transl. Med. 4, 124ra28 (2012).
68. Bridenbaugh, S. et al. Clinical stem-cell sources contain CD8+CD3+T-cell receptor-negative cells that facilitate bone marrow repopulation with hematopoietic stem cells. Blood 111, 1735(2008).
69. Ildstad, S.T. et al. A graft engineering method to allow bone marrow transplantation (BMT) for more highly mismatched recipients with leukemia: Multivariate analysis of a Phase II/III protocol. (Meeting Abstract). Transplant 2000, American Society of Transplant Surgeons and American Society of Transplantation, Chicago, IL, 13-17 May 2000
70. Leventhal, J. et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: Durable chimerism predicts outcome. Transplantation (in press).
71. Xu, H. & Ildstad, S.T. Transplantation: Is donor T-cell engraftment a biomarker for tolerance? Nat. Rev. Nephrol. 8, 560-561 (2012).
72. LoCascio, S.A., Spinelli, J. & Kurtz, J. Hematopoietic stem cell transplantation for the treatment of autoimmunity in type 1 diabetes. Curr. Stem Cell Res. Ther. 6, 29-37 (2011).
73. Pession, A., Zama, D., Masetti, R., Gasperini, P. & Prete, A. Hematopoietic stem cell transplantation for curing children with severe autoimmune diseases: Is this a valid option? Pediatr. Transplant. 16, 413-425 (2012).
74. Milanetti, F., Bucha, J., Testori, A. & Burt, R.K. Autologous hematopoietic stem cell transplantation for systemic sclerosis. Curr. Stem Cell Res. Ther. 6, 16-28 (2011).
75. Milanetti, F., Abinun, M., Voltarelli, J.C. & Burt, R.K. Autologous hematopoietic stem cell transplantation for childhood autoimmune disease. Pediatr. Clin. North Am. 57, 239-271 (2010).